Health ConditionsHistamine intolerance, also referred to as enteral histaminosis or sensitivity to dietary histamine, is a disorder associated with an impaired ability to metabolize ingested histamine that was described at the beginning of the 21st century. More precisely, histamine intolerance results from a disequilibrium of accumulated histamine and the capacity for histamine degradation. Histamine intolerance (HIT) is the term for that type of food intolerance which includes a set of undesirable reactions as a result of accumulated or ingested histamine.
Food intolerance is an abnormal non-immunological response of the organism to the ingestion of food or its components in a dosage normally tolerated. Accordingly, histamine intolerance is distinguished from true IgE-mediated food allergy: food allergy is an inadequate response of the immune system to an antigen ingested in food, that is accompanied by IgE or non-IgE (cellular) immunological mechanisms. Histamine intolerance, by contrast, involves no such immune-mediated mechanism.
Histamine intolerance is a complex pathophysiological condition that significantly impairs the quality of life of those affected by it. While research into this condition continues, the current evidence suggests a myriad of factors contributing to this disease, mainly involving the impaired capacity of the affected individuals to degrade histamine. Individuals affected with histamine intolerance suffer from a multitude of non-specific symptoms that make it challenging to diagnose and manage the disease effectively. Due to limitations in objective and diagnostic tests, histamine intolerance remains a disease diagnosed through clinical exclusion.
It is estimated that the prevalence of HIT is approximately 1% worldwide and that about 80% of those patients are adults. Some estimates place prevalence somewhat higher: some experts think that HIT affects about 1 to 3 people out of 100. Prevalence figures are hampered by inconsistent diagnostic criteria. Prevalence estimates are hampered by the coexistence of diverse diagnostic approaches, aimed to differentiate conditions with different mechanisms and clinical presentations, in which the most common symptoms are gastrointestinal. Roughly 80% of people with diagnosed histamine intolerance are women, often around age 40.
Histamine (2-[4-imidazolyl]ethylamine) is a bioactive amine that is synthesized by decarboxylation of its precursor amino acid, histidine, in an enzymatic reaction involving L-histidine decarboxylase. Histamine is widely present in the human body and can have a wide range of physiological and pathological effects, such as allergy and inflammation, by binding to its specific receptors (H1R, H2R, H3R, H4R).
Histamine is produced endogenously from L-histidine by the enzyme histidine decarboxylase in mast cells, basophils, and several neuronal and immune lineages, whereas exogenous histamine chiefly enters the body through the consumption of fermented, aged, or microbially modified foods rich in biogenic amines.
The body possesses two primary enzymatic pathways for histamine degradation. Based on localisation, histamine can be inactivated by two processes — oxidative deamination of the primary amino group to imidazolacetaldehyde, catalysed by diamine oxidase (DAO, histaminase), or methylation of the imidazole core to N4-methylhistamine catalysed by histamine N-methyltransferase (HNMT). The second major enzyme for metabolism of histamine is histamine-N-methyltransferase (HNMT), which is a cytosolic protein and is therefore only capable of metabolizing intracellular histamine. Reduced function of one or both of the enzymes can lead to histamine imbalance and/or intolerance.
Diamine oxidase (DAO) is a critical enzyme in the regulation of histamine levels, particularly in the gastrointestinal tract, where it degrades exogenous histamine derived from food. DAO is a key enzyme responsible for the metabolism of histamine, preventing its excessive accumulation and thereby maintaining physiological homeostasis. When DAO activity is insufficient, histamine intolerance (HIT) arises, manifesting as migraines, gastrointestinal disturbances, and allergy-like reactions, among other disorders.
In individuals with histamine intolerance, ingestion of food with normal contents of histamine causes histamine-mediated symptoms. HIT is a pathological process in which the enzymatic activity of histamine-degrading enzymes is decreased or inhibited and they are insufficient to inactivate histamine from food and to prevent its passage into the bloodstream.
One of the reasons why the adverse reactions caused by the intake of histamine cannot be clearly defined is their heterogeneity. Due to the fact that histamine enters the circulation and that histamine receptors occur ubiquitously in the human body, a typical clinical picture cannot be strictly defined. The adverse manifestations related to the intake of histamine are usually complex and may affect different organ systems.
The accumulation of histamine in plasma can affect numerous organs and tissues due to the wide distribution of the four histamine receptors in the organism, resulting in a plethora of gastrointestinal and extra-intestinal symptoms (i.e., dermatological, respiratory, neurological and hemodynamic complaints).
Histamine intolerance can cause a range of gastrointestinal symptoms, including bloating, abdominal discomfort, gas, diarrhea or constipation, and other related issues. The most frequent and severe manifestations were gastrointestinal, with abdominal distension observed in 92% of patients and postprandial fullness, diarrhea, abdominal pain and constipation in 55–73%.
Impairments of the nervous and cardiovascular systems, such as dizziness, headaches and palpitations, were recorded in second place, followed by respiratory and dermatological symptoms. Other affected systems include the reproductive system (menstrual cramps), the cardiovascular system (tachycardia, hypotonia, and collapse), and the nervous system (headache and migraine).
Histamine receptors are present in the skin; therefore, there will be skin manifestations, including pruritis, flushing, urticaria, dermatitis, and swelling.
Respiratory symptoms associated with histamine intolerance include rhinorrhea, rhinitis, nasal congestion, dyspnea, and sneezing.
Highlighting the complexity of the clinical picture of histamine intolerance, combinations of three or more symptoms involving different organs were recorded in 97% of patients. Due to its nonspecific clinical manifestations (itching, flushing, edema, postprandial abdominal distension, diarrhea, abdominal pain and constipation, dizziness, headache, hypotension, tachycardia, etc.), HIT was often misdiagnosed as other diseases in the past (e.g., food allergy, irritable bowel syndrome, other food intolerance, celiac disease, eosinophilic gastroenteritis, urticaria, systemic mastocytosis, etc.).
Concerning the genetic component of histamine intolerance, researchers have analyzed the polymorphism in genes encoding enzymes related to histamine metabolism, like DAO and L-histidine decarboxylase, among others. The researchers identified over 50 single-nucleotide polymorphisms in the gene encoding DAO, with some of these polymorphisms producing a protein product that has been shown to have an altered activity that promotes histamine intolerance symptoms. Specifically, the most relevant single-nucleotide polymorphisms (SNPs) of the AOC1 gene leading to reduced DAO enzyme activity in the Caucasian population are c.47C>T (rs10156191), c.995C>T (rs1049742), and c.1990C>G (rs10449793).
Gastrointestinal disorders compromising the integrity of the intestinal mucosa may lead to DAO deficiency. Reduced DAO activity can be found in patients with chronic renal failure, viral hepatitis, advanced hepatic cirrhosis, and chronic urticaria. Structural damage to intestinal villi, such as from inflammatory bowel disease, celiac disease, or Crohn's disease, reduces the number of mature enterocytes that produce DAO.
In addition to the impaired degradation of oral histamine due to a lack of DAO, disturbances in the intestinal flora may also lead to increased histamine levels. Some bacteria also seem to synthesize and secrete histamine. Sánchez-Pérez et al. reported a higher proportion of histamine-secreting bacteria (e.g., Staphylococcus, Proteus, Clostridium perfringens, and Enterococcus faecalis) in patients with histamine intolerance in comparison with a healthy control group, and also reported alterations in gut bacterial diversity in histamine intolerant individuals. An intestinal dysbiosis could not be, by itself, the only cause of histamine intolerance but would probably aggravate the symptoms derived from other primary causes of a DAO deficiency (genetic or pathological).
In 2018, Schink compared microbial patterns from 33 healthy individuals with 33 persons with suspected HIT, 8 of whom had decreased DAO enzyme activity in serum. In comparison with those patients suspected of HIT presence, the healthy people showed a greater abundance of the Bifidobacteriaceae family. In persons having decreased DAO activity in serum, a greater abundance of the Proteobacteria genus was observed.
Among the factors increasing the sensitivity of individuals to the ingestion of histamine are other biogenic amines, alcohol (which blocks the enzyme DAO and can release endogenous histamine), specific medications (with an inhibitory effect on DAO), and malnutrition, leading to an insufficiency of enzyme cofactors (vitamin C, copper, vitamin B6).
The ingestion of histamine-rich food or of alcohol or drugs that release histamine or block DAO may provoke diarrhea, headache, rhinoconjunctival symptoms, asthma, hypotension, arrhythmia, urticaria, pruritus, flushing, and other conditions in patients with histamine intolerance. Certain drugs can interfere with levels of DAO in the body. For example, this can include drugs such as certain proton pump inhibitors (PPIs) and nonsteroidal anti-inflammatory drugs (NSAIDs).
Estrogen stimulates the release of histamine and down-regulates the production of diamine oxidase (DAO), an enzyme that breaks down histamine. This increases the total amount of histamine and reduces the body's ability to break it down. Conversely, histamine stimulates the production of estrogen, creating a vicious cycle. Roughly 80% of people with diagnosed histamine intolerance are women, often around age 40, a pattern consistent with this estrogen–histamine relationship. Rising estrogen (puberty, pre-ovulation, perimenopause) leads to more histamine release and less DAO clearance, while low progesterone reduces mast cell stability and worsens histamine control.
Decreased degradation capacity of DAO can be caused by lack of its cofactors: vitamin B6, vitamin C, copper, and zinc. Studies link HIT to DAO deficiency and/or impaired DAO activity, often in subgroups with genetic, pathological, or pharmacological factors. DAO cofactor deficiencies like copper, zinc, vitamin C, or vitamin B6 may exacerbate DAO impairment.
For proper function of DAO enzyme, its cofactors are important — vitamins B6 and C and copper. Vitamin B6, also known as pyridoxine, acts as a cofactor for many enzymatic reactions, including those that control neurotransmitter and histamine metabolism. A deficiency in Vitamin B6 can lead to decreased DAO activity, exacerbating histamine intolerance symptoms.
Analyses based on functional vitamin B6 levels demonstrated varying responses to DAO supplementation. Samples with lower B6 levels (below 7 µg/l) exhibited minimal to no additional elimination despite supplemental DAO at 6 U/mL. These findings underscore the nuanced interplay among DAO levels, histamine elimination, and the influence of vitamin B6, providing insights into factors impacting histamine metabolism across diverse patient profiles. This study, published in Clinical Chemistry (Oxford Academic), was a clinical laboratory analysis, not a controlled intervention trial; it provides mechanistic support but not direct therapeutic evidence.
Research suggests supplementing with minerals and vitamins like copper, zinc, vitamin C, and vitamin B6 in the case of known deficiency, malnutrition, or restrictive diet. This is because such elements are cofactors for the DAO enzyme and should be used in conjunction with other approaches. Evidence for B6 supplementation in HIT is primarily mechanistic and observational; robust randomized controlled trials specifically evaluating B6 supplementation as an isolated intervention in HIT are lacking.
Vitamin C has been used historically as a broad-spectrum antioxidant and immune-supporting nutrient in many traditional systems of medicine. Its application specifically to histamine-related symptoms is a more recent development arising from 20th-century nutritional biochemistry, rather than ancient herbal tradition.
Analysis of 437 human blood samples has shown that when the plasma-reduced ascorbic acid level falls below 1 mg/100 ml, whole blood histamine levels increase. This inverse relationship, documented by Clemetson in The Journal of Nutrition (1980), was a cross-sectional human study providing foundational observational evidence.
In a study investigating the acute effect of 7.5 g of intravenous vitamin C on histamine levels in 89 patients with allergies or upper respiratory infections, a significant reduction in histamine levels was observed. Furthermore, the decline in histamine concentration after ascorbic acid administration was positively correlated with the basal (pre-therapeutic) histamine concentration. Intravenous infusion of ascorbic acid clearly reduced histamine concentrations in serum, and may represent a therapeutic option in patients presenting with symptoms and diseases associated with pathologically increased histamine concentration. These findings (Hagel et al., published in Naunyn-Schmiedeberg's Archives of Pharmacology, 2013) are from an open-label, non-randomized observational clinical study and should be interpreted with appropriate caution regarding causality. The effect of vitamin C on histamine blood levels has been investigated in both preclinical and clinical studies, but the detailed mode of action has not been fully elucidated.
Decreased degradation capacity of DAO can be caused by lack of its cofactors: vitamin B6, vitamin C, copper, and zinc. Copper is incorporated into the active site of the DAO enzyme and is structurally required for its catalytic function. Some authors regard supplementation of cofactors of the DAO enzyme as optional adjunctive therapy. Vitamin C, copper, or vitamin B6 supplementation may be considered.
Evidence for copper supplementation in HIT is indirect. It derives primarily from biochemical studies of DAO structure and function, and from human studies showing that DAO cofactor deficiencies exacerbate HIT symptoms. No dedicated randomized controlled trials of copper supplementation specifically in HIT populations have been identified in the peer-reviewed literature. The recommendation for copper repletion in verified deficiency states is supported by expert consensus and mechanistic reasoning.
DAO cofactor deficiencies like copper, zinc, vitamin C, or vitamin B6 may exacerbate DAO impairment. Like copper, zinc is referenced in the HIT literature as a potential cofactor influencing DAO function. For proper function of DAO enzyme, cofactors including vitamin B6, vitamin C, and copper are important. DAO protein, stored in vesicular structures, bonds to plasma membrane of cells and is released into circulation after stimulation and is responsible for degradation of extracellular histamine.
The evidence for zinc specifically in HIT is largely mechanistic and indirect. It appears in clinical review articles alongside other cofactors, and its role is considered secondary to copper and vitamin B6. No isolated clinical trials on zinc supplementation for HIT were identified.
Quercetin is a polyphenolic flavonoid found abundantly in foods such as onions, apples, capers, and leafy vegetables. It has been used in traditional herbal medicine systems — including in preparations from elder flower, chamomile, and St. John's wort — though historically these preparations were not isolated specifically for quercetin content or applied to the concept of "histamine intolerance" as a distinct condition. Its use in relation to histamine and allergic conditions is a product of modern phytochemical research.
Quercetin inhibits mast cell degranulation, reduces the production of histamine and pro-inflammatory cytokines, and restores homeostasis of the immune system by modulating the Th1/Th2 and Treg/Th17 balances. In vitro studies have consistently demonstrated quercetin's ability to suppress allergic reactions. In vivo studies, particularly in murine models of allergic rhinitis, have confirmed its efficacy in relieving symptoms and dampening type 2 mucosal inflammation. Preclinical evidence also supports its therapeutic potential in asthma, conjunctivitis, atopic dermatitis, and food allergies. However, human studies are still scarce, as only two clinical trials investigated quercetin as a monotherapy.
An early in vitro study published in PubMed (Pearce et al., 1984) demonstrated that the flavonoid inhibition of antigen-induced histamine secretion from rat intestinal mast cells was immediate and did not decrease on preincubation. Other flavonoids such as acacetin, apigenin, chrysin, and phloretin also demonstrate significant activity but are less potent than quercetin. This is in vitro animal-tissue data only. Quercetin is a natural small molecule compound derived from plants and vegetables that has been shown to prevent histamine release by immune cells, though this evidence base remains predominantly preclinical. Overall, quercetin's evidence for HIT specifically is preliminary — primarily in vitro and animal-based, with limited clinical trial data in humans.
Recent clinical trials support exogenous DAO supplementation for managing histamine intolerance. Exogenous DAO preparations are primarily derived from porcine kidney or, in some formulations, plant sources (such as pea seedlings).
DAO supplementation has been shown to potentially contribute to histamine degradation in the intestinal lumen, but its activity varies depending on the presence of cofactors and the enzyme's origin. Limited clinical evidence reflects the difficulty of dietary management and suggests a beneficial role of DAO supplementation on the clinical manifestations associated with HIT.
All available studies have reported significant reductions of HIT-associated symptoms as a result of DAO supplementation. Specifically, DAO of porcine origin has demonstrated observed improvements when administered at a dose of 4.2 mg before meals.
To date, around twenty studies have investigated the effectiveness of these dietary strategies (low-histamine diet and DAO supplementation) in reducing the frequency and/or intensity of symptoms, with promising results. However, the limitations of these studies — small patient cohort, lack of control group, and short dietary intervention periods — highlight the need for more ambitiously designed research. A large prospective, double-blind, randomized, placebo-controlled trial is underway at the University of Barcelona to address these gaps (Nutrients, published 2024–2025).
Fermented foods containing live bacteria have been consumed across many cultures for millennia (kefir, yogurt, sauerkraut, miso, etc.). However, many traditionally fermented foods are themselves high in biogenic amines and can worsen histamine intolerance symptoms. The selective therapeutic use of specific probiotic strains in HIT is a contemporary concept without a distinct traditional framework.
Supplementation with probiotic microorganisms could lead to modulations of the microbiome that would reduce the production of the microbial enzyme L-histidine decarboxylase. The precondition is the administration of strains that do not produce L-histidine decarboxylase. In an ideal case, these would be strains capable at the same time of degrading histamine. Clinical trials assessing the possible impact of probiotic administration in HIT are not found in literature up to the present.
A study investigated the probiotic Lactiplantibacillus plantarum LP115 and its effect on histamine metabolism. In vitro tests on HT-29 intestinal cells showed that after 4 h of contact, the probiotic significantly increased the secretion of diamine oxidase (DAO), the key enzyme in degrading histamine, and reduced histamine levels in the culture medium. No toxicity was observed. The probiotic did not alter DAO protein expression, suggesting the release of preformed DAO vesicles. Findings support the potential of L. plantarum LP115 in managing histamine intolerance. This is in vitro evidence only.
From experimental trials, it would seem at present that members of the Bifidobacterium genus could be considered as candidates for appropriate supplementation, but studies confirming this assumption are warranted. Critically, as excess histamine is deleterious to the host, the identification of bacterial producers has contributed to concerns over the consumption of probiotics or live microorganisms in fermented food items. Many popular probiotic strains produce histamine or other biogenic amines as a byproduct of their normal fermentation activity — and for someone already struggling to break down dietary histamine, adding more through a supplement can make symptoms significantly worse.
Histamine is a biogenic amine that occurs to various degrees in many foods. The principal dietary sources are foods that have undergone microbial fermentation, aging, or decomposition, during which bacteria decarboxylate histidine to histamine. These include aged and ripened cheeses, fermented sausages and cured meats, fermented vegetables (sauerkraut, kimchi), alcoholic beverages (especially wine and beer), vinegar, and fish products — particularly canned, smoked, or otherwise preserved fish.
Some substances (histamine liberators) have the ability to release histamine from endogenous reserves in the organism. Food triggers (histamine liberators) are foods rich in biogenic amines (canned food, wine, beer, and cheeses), as well as alcohol. Beyond direct histamine content, certain foods are considered to act as liberators that trigger endogenous histamine release from mast cells, including tomatoes, strawberries, citrus fruits, and chocolate, though the clinical significance of this mechanism is debated and the evidence is not as robust as for directly histamine-rich foods.
DAO activity can be reduced by a number of foods (blockers) and drugs (from standard NSAIDs to antidepressants), with diets low in the cofactors vitamin B6, magnesium, and copper also known to exacerbate histamine intolerance symptoms by directly hindering DAO activity. Alcohol is a well-characterized DAO inhibitor, and green and black tea have also been identified in clinical literature as substances that may inhibit DAO activity.
Among therapeutic approaches, the gold standard is a low-histamine diet. The diagnosis is hampered by the lack of a validated biomarker and is mainly based on clinical assessment and response to a low-histamine diet and reintroduction. The therapeutic approach is centered on dietary management, restricting foods that may increase circulating histamine levels.
Patients usually respond to a low-histamine diet in a few days, and the diet should be kept up for one month in responders (subjects no longer with symptoms); foods withdrawn are then gradually reintroduced one by one. Overall, fresh foods are advisable, whilst processed, preserved, and highly elaborated foods should be avoided.
A balanced approach to dietary management is recommended: the main management strategy for HIT is a diet low in components that may increase circulating histamine levels. However, it is recommended to establish a tolerance level of foods that may increase circulating histamine to avoid highly restricting diets. A structured reintroduction protocol is proposed to help individuals identify their personal histamine tolerance threshold, complemented by DAO enzyme supplementation to better manage dietary histamine load.
A preliminary study was carried out aiming to evaluate the potential changes in the composition of the intestinal microbiota in a group of five women diagnosed with histamine intolerance undergoing 9 months of the dietary treatment of histamine intolerance. After sequencing bacterial 16S rRNA genes and analyzing the data, a reduction was observed in certain histamine-secreting bacteria, including the genera Proteus and Raoultella and the species Proteus mirabilis. Moreover, it was also observed an increase in Roseburia spp., a bacterial group frequently related to gut health. This was a small pilot study (n=5) and its findings are preliminary. Some unwanted effects on the microbiome could be explained by the exclusion of FODMAPs and lactose — described as dietary carbohydrates with prebiotic actions — and gluten-containing foods such as wheat or barley, which are a source of prebiotic fructans.
Chronic stress elevates cortisol and influences mast cells to release histamine; it also impacts progesterone. Elevated cortisol levels can destabilise mast cells, which store and release histamine, leading to increased histamine release. The interaction between the hypothalamic-pituitary-adrenal (HPA) axis and mast cell activity is an area of active research, but evidence specific to HIT intervention studies addressing stress management remains limited.
The enzyme HNMT degrades histamine using the major methyl donor S-adenosylmethionine (SAMe) as a co-factor. It stands to reason that insufficient SAMe — or methylation cofactors such as vitamins B6, B12, and folate — may result in high levels of histamine and that high histamine can deplete SAMe, thereby reducing its availability for other methylation reactions. This mechanistic hypothesis is supported by the known biochemistry of methylation pathways, but direct intervention studies in HIT populations are not yet established.
Estrogen tells mast cells to release histamine, which is a big part of why symptoms often get worse around ovulation, the week before a period, during perimenopause, or during fertility treatments. Serum DAO levels are markedly lower in the follicular phase than in the luteal phase, which means the same person can look quite different on paper depending on when the blood is drawn, a practical consideration for diagnostic testing.
The problem with a "diagnosis" of HIT is precisely the inconstancy and variety of the manifestations in the same individual following similar stimuli. The diagnosing of HIT therefore requires a complex time-demanding multidisciplinary approach, including the systematic elimination of disorders with a similar manifestation of symptoms.
Although interest in histamine intolerance has considerably grown in recent years, more scientific evidence is still required to help define, diagnose and clinically manage this condition. According to the American Academy of Allergy, Asthma, and Immunology, HIT isn't recognized as a medical condition. This reflects ongoing controversy: the biochemical mechanisms are well characterized, but standardized diagnostic criteria and robust clinical trial data for most interventions remain lacking. The limitations of available studies — including small patient cohorts, lack of control groups, and short dietary intervention periods — highlight the need for more ambitiously designed research.
Bifidobacterium infantis 35624 suppresses histamine-related allergic symptoms and demonstrates strong anti-inflammatory effects. In combination with B. longum BB536 (Lac-B), it significantly decreased histamine levels and suppressed histidine decarboxylase and H1 receptor gene expression. It belongs to Bifidobacteriaceae, which is more abundant in healthy subjects than HIT patients.
Bifidobacterium longum is identified as a histamine-degrading probiotic that does not produce histamine. Strain BB536 studied in combination with B. infantis 35624 (mixture called Lac-B) significantly suppressed allergic symptoms and decreased histamine levels, including suppression of histidine decarboxylase gene expression. It is recommended in HIT probiotic protocols.
Bovine kidney is a natural source of diamine oxidase (DAO), the primary intestinal enzyme responsible for degrading dietary histamine. Reduced DAO activity is a central mechanism in histamine intolerance (HIT). Clinical studies using kidney-derived DAO supplements have demonstrated symptom improvement in HIT patients. Evidence comes from open-label interventional and retrospective cohort studies.
Copper is a structural and catalytic component of the DAO enzyme, essential for its function. Copper deficiency directly reduces DAO activity, impairing histamine degradation and potentially causing or exacerbating histamine intolerance. Copper is identified as a required cofactor in peer-reviewed HIT literature.
Diamine oxidase (DAO) is the principal intestinal enzyme for degrading dietary histamine. Reduced DAO activity is considered the primary mechanism underlying histamine intolerance (HIT). An open-label pilot study (n=28) showed oral DAO supplementation before meals significantly reduced all HIT-related symptoms over 4 weeks, with symptom scores returning when supplementation stopped. A subsequent observational study (n=82) confirmed similar findings.
Lactobacillus plantarum has demonstrated direct histamine-degrading properties and the ability to stimulate DAO secretion from intestinal epithelial cells. A 2025 PMC study (LP115 strain) showed significant DAO secretion increase and histamine reduction in HT-29 intestinal cell models. Multiple strains of L. plantarum can degrade biogenic amines including histamine.
Luteolin is a flavonoid that stabilizes mast cells and inhibits histamine release, showing greater potency than cromolyn sodium in some assays. Animal studies confirm luteolin reduces histamine release from mast cells stimulated by histamine liberators. It is used in clinical practice for mast cell activation and histamine intolerance.
Stinging nettle (Urtica dioica) acts as a natural antihistamine through H1 receptor antagonism and mast cell tryptase inhibition, mechanisms characterized by Roschek et al. (Phytother Res, 2009). A randomized double-blind clinical trial in allergic rhinitis patients found that freeze-dried Urtica dioica reduced allergy symptoms, and a 2017 RCT confirmed significant improvement in symptom severity scores.
Quercetin is a flavonoid that inhibits mast cell degranulation and histamine release, making it relevant for histamine intolerance management. In vitro studies show quercetin equals or exceeds cromolyn sodium in blocking histamine secretion from human mast cells. It also inhibits histamine-induced calcium influx via H4 receptors and reduces pro-inflammatory cytokines IL-6, IL-8, and TNF-α.
Preclinical studies show Schizonepeta suppresses mast cell degranulation and histamine-related signaling, including in IgE-stimulated models. The 2025 systematic review confirmed histamine suppression among its documented effects. Evidence is in vitro/preclinical with no human histamine intolerance trials.
Vitamin B6 (pyridoxine/pyridoxal-5-phosphate) is an essential cofactor for DAO enzyme activity. Deficiency in B6 impairs DAO function, increasing histamine burden. Multiple reviews and mechanistic studies identify B6 repletion as a standard adjunctive strategy for improving DAO activity in histamine intolerance.
Vitamin C acts as both a cofactor for DAO enzyme function and as a direct antihistamine. Multiple studies demonstrate an inverse correlation between plasma vitamin C levels and blood histamine; supplementation with 1–2 g/day has been shown to lower blood histamine levels within days. Intravenous ascorbic acid (Hagel et al., 2013) significantly decreased serum histamine in allergic and non-allergic patients.
Go back